Innohep

Tinzaparin Sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injection solution for subcutaneous, intravenous, and haemodialysis use. It treats and prevents deep vein thrombosis, pulmonary embolism, and provides anticoagulation during haemodialysis in adult patients.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep (tinzaparin sodium) is used in the anticoagulation pathway to prevent and treat thromboembolic conditions.

- Deep vein thrombosis: prevents clot formation and extension in at‑risk patients. - Pulmonary embolism: reduces the risk of embolic events in postoperative or immobilized patients. - Haemodialysis: provides anticoagulation during extracorporeal circulation to maintain circuit patency.

Adverse reactions to Innohep may vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema. - Mild bruising or hematoma at the injection site. - Nausea or mild gastrointestinal upset. - Headache. - Transient elevation of liver enzymes. - Mild, reversible thrombocytopenia.

Serious or Rare Side Effects: - Major bleeding, including gastrointestinal or intracranial hemorrhage. - Heparin‑induced thrombocytopenia (HIT). - Spinal or epidural hematoma following neuraxial procedures. - Severe allergic reactions such as anaphylaxis. - Acute adrenal hemorrhage. - Paradoxical thrombosis despite anticoagulation.

Before initiating Innohep, clinicians should evaluate patient‑specific risk factors and follow recommended monitoring.

- Renal impairment: adjust monitoring as tinzaparin is partially cleared renally. - Bleeding risk: assess for active bleeding or high‑risk lesions prior to therapy. - Surgery or invasive procedures: discontinue according to procedural guidelines. - Concomitant anticoagulants: avoid combined use without specialist supervision. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk (category unknown). - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Innohep may interact with other medicines that affect haemostasis or platelet function.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): may cause uncontrolled bleeding. - High‑dose aspirin or NSAIDs: increase the risk of bleeding. - Thrombolytic agents: additive anticoagulant effect can be hazardous.

Moderate Interactions (Monitor Closely): - Heparin‑induced thrombocytopenia antibodies: cross‑reactivity may occur. - Renally cleared drugs (e.g., aminoglycosides): may affect tinzaparin clearance. - Antiplatelet agents (e.g., clopidogrel): monitor for enhanced bleeding tendency.